Benchmark : Appointment of Non-Executive Directors

Benchmark, the aquaculture biotechnology and food chain sustainability business, announces the appointment of Hugo Wahnish and Yngve Myhre as Non-Executive Directors of the Company with immediate effect.

Hugo Wahnish (65) has over 35 years of experience in the animal health and pharmaceuticals industry, firstly with GlaxoSmithKline, and more recently with Merck during a period of major growth in the organisation. Hugo held the post of Chief Commercial Officer Animal Health at Merck, having responsibility for Merck's commercial operations worldwide. Since stepping down from that role in 2012, Hugo has acted as an independent senior advisor with several multinational companies, private equity groups and consulting firms primarily in the animal health sector. Hugo brings a wealth of international experience to the board of Benchmark, alongside his expertise in aggressively growing businesses and in the commercialisation of medicines and animal health products. Hugo is based in the United States.

Yngve Myhre (48) has more than 20 years experience in the aquaculture sector as a senior executive, adviser and investor. Yngve was chief executive of leading Norwegian salmon producer Salmar, and of international white fish supplier Aker Seafood during periods of successful growth. He is now chairman of Chilean salmon producer Nova Austral, recently acquired by Cargill, and sits on the boards of Mediterranean fish producer Andromeda and Norwegian aquaculture research institute Nofima. Yngve also acts as strategic adviser to investors in the aquaculture sector. Yngve has a very strong track record in Benchmark's focus area of aquaculture, both in the Norwegian and international markets. Yngve is based in Norway.

Information in respect of Hugo Wahnish and Yngve Myhre, as required by Rule 17 and Schedule 2(g) of the AIM Rules for Companies, is set out below.